ROI_001_BlueSMA_YellowCD8a_MagentaCollagen_RedHis3 Gaussian blur.tif

Tumor Evolution & Therapy Response

Translational Cancer Research | Functional Genomics | Computational Biology

News

Bildschirmfoto 2021-12-21 um 21.31.30.png

Resistance evolution of EGFRmut lung cancer published

SFB_logo.png

Happy that we now are part of CRC1399

RIG-I_paper.png

Kinase inhibition + RIG-I agonist paper published

What we do & Why we do it

Our Research Mission

Survival of cancer patients is still primarily limited by insufficient treatment response and the emergence of resistant disease. We are therefore committed to improve cancer treatment by understanding the mechanisms driving tumor development, immune evasion, therapy response and resistance evolution. Our multidisciplinary team develops and employs an array of functional genomics, computational, and in vivo methods. These tools help us on our mission to advance treatment strategies including personalized therapeutic concepts and rational combination therapies towards our ultimate goal of improving patient care.

Utilizing model systems with defined genomic alterations, clinical samples and large scale functional genomics approaches, we aim to address the following translational research questions:

  • How genomic and epigenetic alterations in cancers are shaped during tumor evolution.

  • How therapeutic stress rewires cancer signaling and the tumor microenvironment.

  • How relevant pathways can be identified and targeted therapeutically to exploit collateral sensitivities or synthetic lethality and prevent resistance.

Our Research Environment

We are fortunate to pursue our goals within the highly collaborative and innovative cancer research environment at the University of Cologne. Our affiliations with the Mildred Scheel School of Oncology, the Department of Translational Genomics, and the Center for Molecular Medicine Cologne (CMMC) strongly support our interdisciplinary approaches. Close cooperations with research groups and clinicians within our institution e.g. at the Departments of Pathology, Oncology and with the Lung Cancer Group Cologne as well as with national and international collaborators provide outstanding opportunities to pursue our multidisciplinary and translational research.

Köln Deutschland